Leqvio's label update allows its use as a first-line monotherapy for LDL-C reduction in hypercholesterolemia, reflecting strong PCSK9-targeting evidence. The update addresses an unmet need, as many ...
In the face of tough competition from Apellis and a recent setback with prescribers, Astellas’ geographic atrophy (GA) med Izervay has nabbed a much-needed label update from the FDA. The agency lifted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback